about
Flexible ligand docking to multiple receptor conformations: a practical alternativePericyte-targeting drug delivery and tissue engineeringSomatic DNA mutation analysis in targeted therapy of solid tumoursReview article: the biology, diagnosis and management of gastrointestinal stromal tumoursStructural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemiaCrystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG ConformationQSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFRMapping of apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy.Pseudokinases: update on their functions and evaluation as new drug targets.Open Access Could Transform Drug Discovery: A Case Study of JQ1.Prediction of specificity-determining residues for small-molecule kinase inhibitors.Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.The stem cell growth factor receptor KIT is not expressed on interstitial cells in bladderReceptor tyrosine kinases and schistosome reproduction: new targets for chemotherapyCharacterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni.Metabolism considerations for kinase inhibitors in cancer treatmentSerum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor ImatinibA phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.Detection of cell aggregation and altered cell viability by automated label-free video microscopy: a promising alternative to endpoint viability assays in high-throughput screening.Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemiaTargeting invadopodia to block breast cancer metastasisIn-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.Exploiting antitumor immunity to overcome relapse and improve remission duration.The ins and outs of bcr-abl inhibition.Imatinib mesylate in the treatment of hematologic malignancies.Somatic pharmacogenomics in cancer.Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitorsAntiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.Outcomes in 11 patients with dermatofibrosarcoma protuberans treated with Mohs micrographic surgery.Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Opening the door to the development of novel Abl kinase inhibitors.Surfaceome profiling reveals regulators of neural stem cell function.Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions.The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF.In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
P2860
Q24650066-207B1C34-CFF4-4083-AF4A-0A6CAE605BB5Q26745598-34C1CCD9-589F-420B-829C-8E68EEB0D52CQ26770324-1D196EC6-EF89-4D3C-AF0F-2147F9FCAF12Q26825310-BAB2CEC0-CC75-4A28-8E71-AB538C1DE2A4Q27640723-D37615FD-903D-453F-ABF8-CFA20D92AF4AQ27652985-BB97540E-1B93-4300-9B4D-C3EF63B4BD01Q28540324-DEF8FB0C-91FF-4A8A-9A36-B6ECFC74BD58Q30009317-389B93B9-0B56-4376-89D8-5AA0ED5C5A8AQ30397636-770B7BC3-A39A-4EC0-8F98-F6B5716084B7Q30488815-27D5E598-9A33-4046-A5A6-E37FF06AB207Q33387038-BE933756-FF46-40DB-8F64-8AE8C3E89B9BQ33631185-C7C82E0C-CF79-4188-B3B7-12843E90D2D8Q33684156-191C046F-BC5C-4732-98EA-A2ED7D2C8457Q33917776-46B2B42E-B693-41F6-8399-92DD16074909Q34052174-E2897F68-C0A8-466A-9D60-C457A3499B07Q34134390-32BD47D7-7497-445E-8DC6-8983E71498C8Q34705820-1466B1CD-EDD6-4123-BDAB-57D57543EF6EQ35089528-703EBF4D-9C5C-423C-8BA2-C34E21F6FAF5Q35529109-0F22C47D-0C9E-40A2-8018-E8FC1C102477Q35550174-7D7571BD-F21F-4B5F-8C0E-742A2CB3424CQ35640216-106FC5E4-A30F-4AA5-8B95-D42C52E2164CQ35812209-EA2AD952-2C5A-4251-B3CD-2CDBC9662C87Q36044604-219EE8F3-7855-462A-A477-B0C97D77E874Q36443401-78194E83-3E3F-48B2-B45E-C7B166EDC651Q36960525-552B61C5-8DC1-4446-A99B-2CC65137F04DQ37235024-DD83A55F-D6ED-4322-AFC0-FF1D5E982EC1Q37382109-B02DC247-4EFC-4190-B79E-F6C94EFF645EQ37669202-88DEB1F2-BE21-458F-9CDF-160833E41DF0Q37969837-AB7E7804-115F-43F4-8F01-EDF1CAE9CC37Q38261599-B14A9973-4EEA-47C1-A3A2-007795DC33D1Q38268165-C15B91C1-6350-489D-9DEF-C092E9411C25Q38580461-0A3933B6-2B8C-4F61-A899-E4A23A2E5AE8Q38806783-5F71007A-39D9-41D1-B96B-3B046C40A0D1Q39097529-DCE10FCC-BDFB-47E6-84EA-597BCA95CA4AQ39226865-0873DB7A-57B3-45D1-9A82-E924B3E9539DQ39560865-C9F7F814-4566-403B-BE79-CC072647BF61Q39580226-B53A6290-4476-45DF-AC15-0DB72B20C247Q40053805-00E27F7A-B1BB-435F-9004-0633BA446EEFQ40453593-7614E75F-9880-4BBB-8275-634EBB5B3BB9Q40477521-8F16E225-2F8C-4C7D-A1AE-FF3874905D5E
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Imatinib: a selective tyrosine kinase inhibitor.
@en
type
label
Imatinib: a selective tyrosine kinase inhibitor.
@en
prefLabel
Imatinib: a selective tyrosine kinase inhibitor.
@en
P2093
P1476
Imatinib: a selective tyrosine kinase inhibitor.
@en
P2093
Buchdunger E
Cowan-Jacob SW
Fendrich G
Zimmermann J
P304
P356
10.1016/S0959-8049(02)80599-8
P478
38 Suppl 5
P577
2002-09-01T00:00:00Z